Allergan PLC, which last year agreed to merge with Pfizer Inc., on Thursday said it will buy clinical-stage pharmaceutical company Anterios Inc.
Under the terms of the deal, Allergan will pay Anterios $90 million up front, plus milestone payments.
Anterios is the developer of NDS, a technology that delivers neurotoxins through the skin instead of through injection. Allergan is perhaps best known as the maker of Botox, a neurotoxin with both cosmetic and therapeutic variations used to treat everything from wrinkles to osteoarthritis.
In a news release, Allergan Executive Vice President David Nicholson said the deal allows Allergan to advance “a new delivery system and formulations that are appealing to both patients and physicians.”
Allergan also will get global rights to ANT-1207, a topical drug being investigated for the use of excessive sweating, acne and crow’s feet.
Allergan in November agreed to a more than $150 billion tie-up with Pfizer, a historic merger that would create the world’s biggest drugmaker. The combined company will have top-selling products including Pfizer’s Prevnar pneumonia vaccine and Allergan’s Botox, and an industry-topping R&D budget.
By Chelsey Dulaney
Source: Wall Street Journal
Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.
Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.
Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.
